A new study finds that biologic therapies significantly reduce the risk of heart attacks and strokes in patients with psoriasis or psoriatic arthritis. Learn more about the cardiovascular benefits of ...
While pharmacologic therapies remain central to managing PsO and PsA, non-pharmacologic interventions also play a crucial ...
20h
Delays in diagnosing and treating psoriatic arthritis—a common inflammatory disorder affecting around 200,000 people in the U ...
Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug ...
Investigators compared outcomes among patients with psoriasis undergoing apremilast treatment with genital involvement versus those without genital involvement.
Psoriasis results in long-term inflammation in the body. This inflammation stiffens and narrows the arteries, raising the ...
PRNewswire/ -- ixlayer, a leading cloud-based healthtech platform, with Ipsos, a global leader in market research, have released findings from the inaugural research report, " ixlayer ixInsights 2025: ...
Proprietary master cell bank of fibroblast-based spheroids product candidate, CYWC628, completed in accordance with Good Manufacturing Practices ...
A panelist discusses how new data from the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates tildrakizumab’s efficacy in treating nail psoriasis, with the 100-mg dose showing ...
The findings highlight the potential benefits of newer biologics targeting IL-12, IL-23, and IL-17 while also raising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback